- authorisedHuman Pharmacology (Phase I)- First administration to humans
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT)
The FiREBOLT study is testing a new cancer medicine, LY4337713, for the first time in humans. It is for adults with certain solid tumours—such as breast, bowel, or stomach cancer—that carry a protein called FAP. The main goal is to check its safety and find the right dose.
Germany · Netherlands - recruitingPHASE3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
This study is testing a new medicine, Sofetabart Mipitecan, for certain ovarian, fallopian tube, and peritoneal cancers. It aims to see if it works better than current treatments and is safe, for people whose cancer either has or hasn't responded well to previous platinum-based treatments.
United States · Australia · Austria - recruitingPHASE3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
This study is for women with advanced ovarian cancer that has responded well to initial treatment. It's testing a new medicine called sac-TMT, sometimes with bevacizumab, to see if it can keep the cancer from growing or coming back for longer than standard care.
United States · Argentina · Australia - recruitingTherapeutic exploratory (Phase II)
OPAL Master Protocol: A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL) (PR-3000-02-005/213357) Cohort C: Open-label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants with Homologous Recombination- Deficient Stage III/IV Ovarian Cancer
This study looks at new ways to treat advanced ovarian cancer before surgery. It compares a drug called niraparib with standard chemotherapy. Researchers want to see if the new approach is safer and works better for certain types of ovarian cancer.
Spain - recruitingPHASE3
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
This study is looking at a new medicine called Mocertatug Rezetecan (Mo-Rez) for women with ovarian cancer that hasn't responded well to previous platinum-based treatments. It aims to see if Mo-Rez works better or is safer than current standard treatments. It's a key step in understanding this new option.
Australia · Canada · Japan - recruiting
Institut Paoli Calmettes Ovarian Cancer Database
This study is gathering information from patients at Institut Paoli-Calmettes who have been diagnosed with ovarian cancer. Researchers want to better understand ovarian cancer by collecting health details and treatment paths from these patients.
France - active not recruitingPHASE3
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This study is looking at a new medicine called Niraparib to see if it can help women with advanced ovarian cancer stay well for longer after their first round of chemotherapy. It’s comparing Niraparib to a dummy drug (placebo).
United States · Belgium · Denmark - recruiting
Establishment of a Tumor Bank for Blood Samples
This study is setting up a collection of blood samples from people with cancer and healthy volunteers. This collection, called a tumour bank, will help scientists understand cancer better and develop new treatments in the future.
Austria · Belgium · Germany - recruitingPHASE1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.
United States · France · South Korea - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This study looks at two drugs called dabrafenib and trametinib for various cancers with a specific gene change (BRAF V600). These drugs are already approved for some cancers and researchers want to see if they can help people with other rare cancers or cancers with this same change.
United Kingdom - recruitingPHASE2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
This study looks at new treatments (Dostarlimab alone or with Bevacizumab) for certain gynaecological cancers that have come back or not responded to previous treatment, comparing them to standard chemotherapy. It aims to see which treatment works best.
Australia · Hong Kong · Japan - recruitingPHASE1, PHASE2
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
This study is testing a new drug, UCB4594, for advanced cancers. It's the first time it’s being used in people. Researchers want to find the safest dose, understand side effects, and see if it can shrink certain tumours by helping the body's immune system.
United Kingdom - recruitingPHASE1, PHASE2
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
This study is testing a new drug, BMS-986340, by itself and with other treatments for different advanced cancers. Researchers want to find the safest dose and see how well it works. This is the first time BMS-986340 has been tried in people.
United States · Australia · Canada - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This study is for adults with specific cancers that have a change called BRAF V600. It's testing if two drugs, vemurafenib and cobimetinib, already used for a type of skin cancer, can help treat these other cancers. The goal is to find new treatments for patients.
United Kingdom - active not recruitingPHASE3
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
This study looks at a new drug, oregovomab, combined with standard chemotherapy for women with advanced ovarian cancer after surgery. Researchers want to see if this combination works better and is safe compared to chemotherapy alone.
United States · Argentina · Belgium - active not recruitingPHASE3
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
This study compares new drug combinations (dostarlimab and niraparib) with standard care for women newly diagnosed with advanced ovarian cancer. It aims to see if these new treatments can stop the cancer from growing for longer.
United States · Belarus · Belgium - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This study is testing if two drugs, trastuzumab and pertuzumab, can treat different types of cancer beyond breast cancer. These drugs work by targeting a specific change in cancer cells called HER2. It's for people aged 12 and over with HER2-positive cancers.
United Kingdom - active not recruitingPHASE2
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
This study is testing a new drug, disitamab vedotin, for certain advanced cancers like head and neck, lung, ovarian, and endometrial cancer. It's for people whose cancer has a marker called HER2 and has already been treated. The study wants to see how well the new drug works and if it's safe.
United States · Australia · Canada